Sold as Enablex. Every FDA application for this active ingredient: 1 branded and 9 generic.
As of Nov 16, 2026, FDA lists 10 applications for Darifenacin Hydrobromide (sold as Enablex), first approved Dec 22, 2004, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Darifenacin ER | Part D | $4.5M | -33% | 10,045 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALSAmyotrophic Lateral Sclerosis · Oliver Blanchard | Phase 2 | Recruiting | Feb 8, 2024 |
| Dec 22, 2004 | EnablexNDA 21513 · New molecular entity | Abbvie | 14 | Discontinued |
| Mar 13, 2015 | Darifenacin HydrobromideANDA 91190 | Ph Health | 0 | Discontinued |
| Sep 1, 2016 | Darifenacin HydrobromideANDA 207664 | Cipla | 1 | Marketed |
| Sep 19, 2016 | Darifenacin HydrobromideANDA 206743 | Aurobindo Pharma | 0 | Marketed |
| Oct 12, 2016 | Darifenacin HydrobromideANDA 205550 | Jubilant Generics | 0 | Discontinued |
| Nov 17, 2016 | Darifenacin HydrobromideANDA 205209 | Torrent | 1 | Marketed |
| Jul 28, 2017 | DarifenacinANDA 207302 | Macleods Pharms | 0 | Marketed |
| Dec 8, 2017 | Darifenacin HydrobromideANDA 207681 | Alembic | 0 | Marketed |
| Oct 22, 2019 | Darifenacin HydrobromideANDA 209571 | Xiromed | 0 | Discontinued |
| Jan 6, 2020 | Darifenacin HydrobromideANDA 211045 | Alicora | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA